Inventor · disambiguated record
Michael Oestergaard
Also filed as: OESTERGAARD MICHAEL
19 granted patents·25 pending applications·62 citations·filing 2012–2025
93Inventor score
Files withIONIS PHARMACEUTICALS INC38ASTRAZENECA AB2ISIS PHARMACEUTICALS INC1OESTERGAARD MICHAEL1SETH PUNIT P1
Top patents by PatentIndex Score
44 records- 0198US11236335B2Selective antisense compounds and uses thereofIONIS PHARMACEUTICALS INC·Filed 2020·Granted Feb 1, 2022·6 cites·24 claims
- 0296US11149264B2Modified compounds and uses thereofIONIS PHARMACEUTICALS INC·Filed 2021·Granted Oct 19, 2021·5 cites·29 claims
- 0394US11732261B2Selective antisense compounds and uses thereofIONIS PHARMACEUTICALS INC·Filed 2020·Granted Aug 22, 2023·2 cites·20 claims
- 0494US10344275B2Linkage modified oligomeric compoundsIONIS PHARMACEUTICALS INC·Filed 2018·Granted Jul 9, 2019·8 cites·21 claims
- 0593US10260069B2Selective antisense compounds and uses thereofIONIS PHARMACEUTICALS INC·Filed 2014·Granted Apr 16, 2019·10 cites·12 claims
- 0693US10202599B2Selective antisense compounds and uses thereofSETH PUNIT P·Filed 2012·Granted Feb 12, 2019·8 cites·18 claims
- 0791US11332733B2Modified compounds and uses thereofIONIS PHARMACEUTICALS INC·Filed 2019·Granted May 17, 2022·4 cites·20 claims
- 0891US2025270554A1Selective Antisense Compounds and Uses ThereofIONIS PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 0991US2024368592A1Selective Antisense Compounds and Uses ThereofIONIS PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1090US11629348B2Linkage modified oligomeric compounds and uses thereofIONIS PHARMACEUTICALS INC·Filed 2022·Granted Apr 18, 2023·2 cites·28 claims
- 1190US9926556B2Linkage modified oligomeric compoundsIONIS PHARMACEUTICALS INC·Filed 2015·Granted Mar 27, 2018·5 cites·21 claims
- 1289US9752142B2Gapped oligomeric compounds comprising 5′-modified deoxyribonucleosides in the gap and uses thereofOESTERGAARD MICHAEL·Filed 2012·Granted Sep 5, 2017·7 cites·26 claims
- 1389US2024141343A1Selective Antisense Compounds and Uses ThereofIONIS PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1488US11116843B2Conjugated antisense compounds and their useIONIS PHARMACEUTICALS INC·Filed 2016·Granted Sep 14, 2021·3 cites·16 claims
- 1587US2025354135A1Modified Compounds and Uses ThereofIONIS PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 1683US2023113863A1Selective Antisense Compounds and Uses ThereofIONIS PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 1782US12275940B2Conjugated antisense compounds and their useIONIS PHARMACEUTICALS INC·Filed 2023·Granted Apr 15, 2025·0 cites·18 claims
- 1882US12152244B2Selective antisense compounds and uses thereofIONIS PHARMACEUTICALS INC·Filed 2022·Granted Nov 26, 2024·0 cites·14 claims
- 1981US2024294923A1Selective Antisense Compounds and Uses ThereofIONIS PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 2080US11725208B2Conjugated antisense compounds and their useIONIS PHARMACEUTICALS INC·Filed 2018·Granted Aug 15, 2023·1 cites·33 claims
- 2179US12234447B2Modified compounds and uses thereofIONIS PHARMACEUTICALS INC·Filed 2022·Granted Feb 25, 2025·0 cites·21 claims
- 2279US2025368995A1Linkage Modified Oligomeric Compounds and Uses ThereofIONIS PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 2378US2025376683A1Selective Antisense Compounds and Uses ThereofIONIS PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 2476US2021147838A1Selective Antisense Compounds and Uses ThereofIONIS PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 2572US2024293563A1Glp-1 receptor ligand moiety conjugated oligonucleotides and uses thereofASTRAZENECA AB·Filed 2024·Application pending·0 cites
- 2672US2025333741A1Conjugated Antisense Compounds and Their UseIONIS PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 2771US2019276823A1Selective antisense compounds and uses thereofIONIS PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 2871US2024325425A1Allele-selective compounds and methods for modulating huntingtin expressionIONIS PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 2970US9714288B2Antisense compounds and uses thereofUNIV CALIFORNIA·Filed 2015·Granted Jul 25, 2017·1 cites·16 claims
- 3068US2017130224A1Linkage modified gapped oligomeric compounds and uses thereofIONIS PHARMACEUTICALS INC·Filed 2017·Application pending·0 cites
- 3168US2022023429A1Conjugated antisense compounds and their useIONIS PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 3267US2015275208A1Selective antisense compounds and uses thereofISIS PHARMACEUTICALS INC·Filed 2013·Application pending·0 cites
- 3366US2020056187A1Selective antisense compounds and uses thereofIONIS PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 3465US2025177433A1Compounds and methods for reducing dmpk expressionIONIS PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 3563US10865413B2Oligomeric compounds comprising α-β-constrained nucleic acidIONIS PHARMACEUTICALS INC·Filed 2019·Granted Dec 15, 2020·0 cites·20 claims
- 3662US2017327824A1Selective antisense compounds and uses thereofIONIS PHARMACEUTICALS INC·Filed 2017·Application pending·0 cites
- 3759US2025154506A1Linkage modified oligomeric compounds and uses thereofIONIS PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 3859US2024382605A1Conjugated oligonucleotides and uses thereofIONIS PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 3953US10221416B2Oligomeric compounds comprising alpha-beta-constrained nucleic acidIONIS PHARMACEUTICALS INC·Filed 2015·Granted Mar 5, 2019·0 cites·24 claims
- 4052US2020268898A1Glp-1 receptor ligand moiety conjugated oligonucleotides and uses thereofASTRAZENECA AB·Filed 2018·Application pending·0 cites
- 4151US2021380976A1Chirally enriched oligomeric compoundsIONIS PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 4247US11180756B2Morpholino modified oligomeric compoundsIONIS PHARMACEUTICALS INC·Filed 2018·Granted Nov 23, 2021·0 cites·9 claims
- 4342US2021052631A1Conjugated antisense compounds and their useIONIS PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 4440US2018010126A1Antisense compounds and uses thereofIONIS PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Michael Oestergaard files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →